secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibitor Therapeutics, Inc. (INTI)
CIK:        0001042418
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001193125-23-258156
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibitor Therapeutics appoints Michelle Yanez as director, forms Scientific Advisory Board
--------------------------------------------------------------------------------

- Michelle Yanez appointed as independent director and Audit Committee member, effective Oct 13, 2023.
- Company creates SAB to advise on clinical development; Dr. Elizabeth Billingsley named chairperson.
- Consulting agreement with Dermapharm Consulting LLC (Dr. Billingsley) at $600/hour for clinical trial support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042418/000119312523258156/0001193125-23-258156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042418/000119312523258156/d562103d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-258156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer